NEW DELHI, INDIA, Thursday, June 30, 2011 -- Bausch + Lomb, the
global eye health company, today announced plans to launch a
pharmaceutical business in India through a strategic agreement with
Micro Labs, a leading provider of quality healthcare products. The
partnership will provide Bausch + Lomb with high-quality manufacturing
capabilities in the region that will speed the introduction of new
prescription and over-the-counter medicines targeted at a wide range of
Through the agreement with Micro Labs, Bausch + Lomb aims to capture
part of the rapidly expanding ophthalmic pharmaceuticals market in India
which is expected to reach US$300 million by 2015. In addition to
gaining access to world class manufacturing capabilities, Bausch + Lomb
will establish dedicated sales and marketing teams, and deliver
practitioner and patient education programs designed to improve the
quality of, and access to, eye care.
“With as many as 76% of patients suffering from eye disease in India
going untreated, Bausch + Lomb believes this is a critical time to enter
the market with medicines and education designed to improve patient
outcomes and overall quality of life,” said Mr. Dan Wechsler, corporate
vice president and global president, Bausch + Lomb Pharmaceuticals.
“Today ophthalmic pharmaceuticals represent the fastest-growing segment
of our business globally, and our collaboration with Micro Labs will
enable us to enter one of the world’s most vibrant yet underserved
markets in the world with high-quality and dependable products that may
help people see and live better.”
The companies will introduce up to six new pharmaceuticals eye drops
including Moxisurge™, Aquasurge™, Aquasurge Max™, Bromvue™, Ketovue™ and
Moxisurge-KT™. Furthermore, the companies have also agreed to explore
other areas of possible collaboration including:
- Sourcing of Ophthalmic Solution products from Micro Labs to be
marketed and sold by Bausch + Lomb in India and other markets in Asia
- Collaboration between the companies with respect to manufacturing technology for the production of eye drops.
- Joint research & development of Ophthalmic Pharmaceutical products specifically for emerging markets.
“It gives us immense pleasure to partner with Bausch + Lomb, the most
powerful brand in eye health as they enter into the Pharmaceutical
segment in India,” said Mr. Anand Surana, director, Micro Labs, India.
“Our collaboration demonstrates that pharmaceutical manufacturing in
India has come of age and our products meet the most stringent global
Bausch + Lomb began commercial operations in India in 1992 with its
contact lens and solutions business before expanding into eye-related
surgery products in 1996. Today Bausch + Lomb is the market leader for
lenses and solutions in India and one of the fastest growing
multinational corporations in Surgical Ophthalmology in the region.
“Bausch + Lomb is committed to improving the quality of eye care in
India, and to helping doctors grow their practices and expand the range
of offerings they provide,” said Harish Natarajan, managing director,
Bausch + Lomb India. “Our collaboration with Micro Labs will help us do
both quickly and with quality.”
About Bausch + Lomb
Bausch + Lomb is one of the best-known and most respected
healthcare companies in the world. Its core businesses include contact
lenses and lens care products, ophthalmic surgical devices and
instruments, and ophthalmic pharmaceuticals. Founded in 1853, the
company is headquartered in Rochester, N.Y., and employs more than
10,000 people worldwide. Its products are available in more than 100
countries. More information is available at www.bausch.com.
About Micro Labs Limited
Micro Labs Limited was established in the year 1973, with an
objective of providing quality healthcare products at an affordable
cost. It has a strong presence in the domestic market in Cardiology,
Diabetology, Neuropsychiatry, Dermatology, Ophthalmology, Antimicrobial
Therapy and pain management. Micro Labs has recently entered the
Nephrology segment. Micro Labs has four overseas offices, and has
invested in creating five subsidiaries in the International markets.
(UK, Philippines, Nigeria, South Africa & Mexico)
The group has presence in over 60 countries,
exporting all major dosages in every therapeutic segment. Being one of
the leading Indian healthcare providers in India, Micro Labs aims to be a
prominent pharmaceutical player in both regulated and non-regulated
markets across the globe.
The R & D team comprises of 200 scientists, pharmacists, analysts,
chemists and microbiologists engaged in product & analytical
development. R&D centre is an integrated set up with three research
Moxisurge™, Aquasurge™, Aquasurge Max™, Bromvue™,
Ketovue™ and Moxisurge-KT™ are registered trademarks of Bausch &